Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK4 | O00444 | 8/20 | 0.53 |
| ▸ | FLT3 | P36888 | 7/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.50 |
| ▸ | KDR | P35968 | 3/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.41 |
| ▸ | ETV6 | P41212 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.39 |
| ▸ | HAMP | P81172 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587218 | 0.91 | PLK4 (0.50) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL13768508 | 0.91 | PLK4 (0.50) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL2557616 | 0.91 | PLK4 (0.50) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL9947227 | 0.91 | PLK4 (0.50) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL12795343 | 0.91 | PLK4 (0.51) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL2543114 | 0.91 | PLK4 (0.57) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL586267 | 0.91 | PLK4 (0.57) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL12795424 | 0.91 | PLK4 (0.42) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL589434 | 0.91 | PLK4 (0.57) | PLK4FLT3AURKAAURKBKDR | |
| SCHEMBL589513 | 0.90 | PLK4 (0.59) | PLK4FLT3AURKAAURKBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9907800-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2018-03-06 | — | — | US | disclosed |
| US-9402828-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2016-08-02 | — | — | US | disclosed |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2016-02-18 | — | — | US | disclosed |
| US-9139563-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2015-09-22 | — | — | US | disclosed |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2015-07-02 | — | — | US | disclosed |
| US-8999968-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2015-04-07 | — | — | US | disclosed |
| US-8933070-B2 | Methods of targeting PTEN mutant diseases and compositions therefor | UNIVERSITY HEALTH NETWORK (CA) | 2015-01-13 | — | — | US | disclosed |
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIV HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045822-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-02-13 | — | — | US | disclosed |
| US-8481525-B2 | Kinase inhibitors and method of treating cancer with same | UNIVERSITY OF HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-8481533-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-07-09 | — | — | US | disclosed |
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2013-05-16 | — | — | US | disclosed |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2012-10-18 | — | — | US | disclosed |
| US-8263596-B2 | Kinase inhibitors and method of treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2012-09-11 | — | — | US | disclosed |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORKS (CA) | 2012-06-14 | — | — | US | disclosed |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | UNIVERSITY HEALTH NETWORKS (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123273-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | PLK4 23/4885FLT3 516/4885AURKA 794/4885 |
| US-20160045511-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PLK4 267/4885FLT3 163/4885AURKA 149/4885 |
| US-20120264800-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PLK4 267/4885FLT3 163/4885AURKA 149/4885 |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | PLK4 464/4885FLT3 221/4885AURKA 10/4885 |
| US-20150182504-A1 | METHODS OF TARGETING PTEN MUTANT DISEASES AND COMPOSITIONS THEREFOR | PTEN, PIK3CA, HRAS | PLK4 139/4885FLT3 437/4885AURKA 1470/4885 |
| US-20120149686-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | PLK4 281/4885FLT3 175/4885AURKA 108/4885 |
| US-20140045838-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PLK4 267/4885FLT3 163/4885AURKA 149/4885 |
| US-20110263598-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER | MAP3K6, MAP3K5, MAP3K19 | PLK4 267/4885FLT3 163/4885AURKA 149/4885 |
| US-20140045822-A1 | KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | MAP3K5, MAP3K6, MAP3K1 | PLK4 281/4885FLT3 175/4885AURKA 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.